Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18461329rdf:typepubmed:Citationlld:pubmed
pubmed-article:18461329lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18461329lifeskim:mentionsumls-concept:C1556094lld:lifeskim
pubmed-article:18461329lifeskim:mentionsumls-concept:C0023413lld:lifeskim
pubmed-article:18461329lifeskim:mentionsumls-concept:C1522484lld:lifeskim
pubmed-article:18461329lifeskim:mentionsumls-concept:C1527249lld:lifeskim
pubmed-article:18461329lifeskim:mentionsumls-concept:C0123931lld:lifeskim
pubmed-article:18461329lifeskim:mentionsumls-concept:C0036525lld:lifeskim
pubmed-article:18461329lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:18461329lifeskim:mentionsumls-concept:C1521750lld:lifeskim
pubmed-article:18461329lifeskim:mentionsumls-concept:C1446539lld:lifeskim
pubmed-article:18461329lifeskim:mentionsumls-concept:C0936116lld:lifeskim
pubmed-article:18461329lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:18461329lifeskim:mentionsumls-concept:C0585332lld:lifeskim
pubmed-article:18461329lifeskim:mentionsumls-concept:C0701185lld:lifeskim
pubmed-article:18461329pubmed:issue3lld:pubmed
pubmed-article:18461329pubmed:dateCreated2008-12-23lld:pubmed
pubmed-article:18461329pubmed:abstractTextWe aimed to evaluate the safety and efficacy of combination chemotherapy with biweekly irinotecan (CPT-11) plus oral tegafur/uracil (UFT) and leucovorin (LV) in patients with previously untreated metastatic colorectal adenocarcinoma in phase I/II setting.lld:pubmed
pubmed-article:18461329pubmed:languageenglld:pubmed
pubmed-article:18461329pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18461329pubmed:citationSubsetIMlld:pubmed
pubmed-article:18461329pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18461329pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18461329pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18461329pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18461329pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18461329pubmed:statusMEDLINElld:pubmed
pubmed-article:18461329pubmed:monthFeblld:pubmed
pubmed-article:18461329pubmed:issn1432-0843lld:pubmed
pubmed-article:18461329pubmed:authorpubmed-author:EndoTakashiTlld:pubmed
pubmed-article:18461329pubmed:authorpubmed-author:KubotaTetsuro...lld:pubmed
pubmed-article:18461329pubmed:authorpubmed-author:HasegawaHirot...lld:pubmed
pubmed-article:18461329pubmed:authorpubmed-author:IshiiYoshiyuk...lld:pubmed
pubmed-article:18461329pubmed:authorpubmed-author:KitagawaYukoYlld:pubmed
pubmed-article:18461329pubmed:authorpubmed-author:OkabayashiKoj...lld:pubmed
pubmed-article:18461329pubmed:authorpubmed-author:OchiaiHirokiHlld:pubmed
pubmed-article:18461329pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18461329pubmed:volume63lld:pubmed
pubmed-article:18461329pubmed:ownerNLMlld:pubmed
pubmed-article:18461329pubmed:authorsCompleteYlld:pubmed
pubmed-article:18461329pubmed:pagination501-7lld:pubmed
pubmed-article:18461329pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:18461329pubmed:meshHeadingpubmed-meshheading:18461329...lld:pubmed
pubmed-article:18461329pubmed:meshHeadingpubmed-meshheading:18461329...lld:pubmed
pubmed-article:18461329pubmed:meshHeadingpubmed-meshheading:18461329...lld:pubmed
pubmed-article:18461329pubmed:meshHeadingpubmed-meshheading:18461329...lld:pubmed
pubmed-article:18461329pubmed:meshHeadingpubmed-meshheading:18461329...lld:pubmed
pubmed-article:18461329pubmed:meshHeadingpubmed-meshheading:18461329...lld:pubmed
pubmed-article:18461329pubmed:meshHeadingpubmed-meshheading:18461329...lld:pubmed
pubmed-article:18461329pubmed:meshHeadingpubmed-meshheading:18461329...lld:pubmed
pubmed-article:18461329pubmed:meshHeadingpubmed-meshheading:18461329...lld:pubmed
pubmed-article:18461329pubmed:meshHeadingpubmed-meshheading:18461329...lld:pubmed
pubmed-article:18461329pubmed:meshHeadingpubmed-meshheading:18461329...lld:pubmed
pubmed-article:18461329pubmed:meshHeadingpubmed-meshheading:18461329...lld:pubmed
pubmed-article:18461329pubmed:meshHeadingpubmed-meshheading:18461329...lld:pubmed
pubmed-article:18461329pubmed:meshHeadingpubmed-meshheading:18461329...lld:pubmed
pubmed-article:18461329pubmed:meshHeadingpubmed-meshheading:18461329...lld:pubmed
pubmed-article:18461329pubmed:year2009lld:pubmed
pubmed-article:18461329pubmed:articleTitleCombination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.lld:pubmed
pubmed-article:18461329pubmed:affiliationDepartment of Surgery, School of Medicine, Keio University, Shinanomachi, Shinjyuku-ku, Tokyo, Japan.lld:pubmed
pubmed-article:18461329pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18461329pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
pubmed-article:18461329pubmed:publicationTypeClinical Trial, Phase Illd:pubmed